Literature DB >> 19718365

Primary patency of percutaneously inserted self-expanding metallic stents in patients with malignant biliary obstruction.

Ursula Dahlstrand1, Gabriel Sandblom, Lars-Gunnar Eriksson, Rickard Nyman, Ib Christian Rasmussen.   

Abstract

BACKGROUND: Effective bile duct drainage is crucial to the health-related quality of life of patients with jaundice caused by obstruction of the bile duct by inoperable malignant tumours.
METHODS: All patients who were treated at Uppsala University Hospital, Sweden with percutaneous stenting between 2000 and 2005 were identified retrospectively. Data on the location of the obstruction and type of stent used, date and cause of death and date of stent failure were abstracted from the patients' notes. Stent patency was defined as the duration from the insertion of the stent to the date of failure. In cases in which the cause of death was directly related to failure of the stent, the date of death was defined as the patency endpoint.
RESULTS: A total of 64 patients (34 women, 30 men) were identified. Their mean age was 71 years (standard deviation 11 years). The median length of patency was 11.4 months. Stent diameter >10 mm and distal stricture were found to be associated with significantly longer patency time in univariate Cox proportional hazard analysis. In multivariate Cox proportional hazard analysis, only location of the stricture was found to be independently and significantly associated with patency time. DISCUSSION: Percutaneous stenting is a good alternative for patients with obstructive jaundice and a life expectancy < or = 1 year. It may give instant relief from the symptoms associated with jaundice. Patency time may be prolonged by using stents with a diameter > or = 10 mm. However, patency time was found to be lower for hilar tumours.

Entities:  

Keywords:  cholangiocarcinoma; jaundice; pancreatic cancer; patency; stenting

Year:  2009        PMID: 19718365      PMCID: PMC2727091          DOI: 10.1111/j.1477-2574.2009.00069.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  17 in total

Review 1.  Biliary tract cancers.

Authors:  P C de Groen; G J Gores; N F LaRusso; L L Gunderson; D M Nagorney
Journal:  N Engl J Med       Date:  1999-10-28       Impact factor: 91.245

2.  Tannenbaum and metal stents in the palliative treatment of malignant distal bile duct obstruction: a comparative study of patency and cost effectiveness.

Authors:  P Katsinelos; D Paikos; J Kountouras; G Chatzimavroudis; G Paroutoglou; I Moschos; A Gatopoulou; A Beltsis; C Zavos; B Papaziogas
Journal:  Surg Endosc       Date:  2006-08-07       Impact factor: 4.584

3.  Resection or palliation: priority of surgery in the treatment of hilar cancer.

Authors:  H Bismuth; D Castaing; O Traynor
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

4.  Relief of obstructive jaundice through percutaneous transhepatic catheter--a new therapeutic method.

Authors:  W Molnar; A E Stockum
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1974-10

5.  A survival analysis of patients with malignant biliary strictures treated by percutaneous metallic stenting.

Authors:  Elias N Brountzos; Nikolaos Ptochis; Irene Panagiotou; Katerina Malagari; Chara Tzavara; Dimitrios Kelekis
Journal:  Cardiovasc Intervent Radiol       Date:  2007 Jan-Feb       Impact factor: 2.740

Review 6.  Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.

Authors:  D Yip; C Karapetis; A Strickland; C B Steer; D Goldstein
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

7.  Malignant biliary obstruction: percutaneous use of self-expandable stents.

Authors:  J S Laméris; J Stoker; H G Nijs; H M Zonderland; O T Terpstra; M van Blankenstein; H E Schütte
Journal:  Radiology       Date:  1991-06       Impact factor: 11.105

8.  Management of malignant biliary obstruction: technical and clinical results using an expanded polytetrafluoroethylene fluorinated ethylene propylene (ePTFE/FEP)-covered metallic stent after 6-year experience.

Authors:  Fabrizio Fanelli; Gianluigi Orgera; Mario Bezzi; Plinio Rossi; Massimiliano Allegritti; Roberto Passariello
Journal:  Eur Radiol       Date:  2008-01-19       Impact factor: 5.315

9.  Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma.

Authors:  Andreas Weber; Sonja Landrock; Jochen Schneider; Manfred Stangl; Bruno Neu; Peter Born; Meinhard Classen; Thomas Rösch; Roland-M Schmid; Christian Prinz
Journal:  World J Gastroenterol       Date:  2007-03-07       Impact factor: 5.742

10.  Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction.

Authors:  P H Davids; A K Groen; E A Rauws; G N Tytgat; K Huibregtse
Journal:  Lancet       Date:  1992 Dec 19-26       Impact factor: 79.321

View more
  3 in total

1.  Percutaneous trans-hepatic bilateral biliary stenting in Bismuth IV malignant obstruction.

Authors:  Dimitrios Karnabatidis; Stavros Spiliopoulos; Paraskevi Katsakiori; Odissefs Romanos; Konstantinos Katsanos; Dimitrios Siablis
Journal:  World J Hepatol       Date:  2013-03-27

2.  Endoscopic Ultrasound-Guided Versus Percutaneous Transhepatic Biliary Drainage in Patients With Malignant Biliary Obstruction: Which Is the Optimal Cost-Saving Strategy After Failed ERCP?

Authors:  Won Jae Yoon; Eric D Shah; Tae Hoon Lee; Sunguk Jang; Ryan Law; Do Hyun Park
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

3.  Percutaneous biliary drainage for obstructive jaundice in patients with inoperable, malignant biliary obstruction.

Authors:  Enver Zerem; Bilal Imširović; Suad Kunosić; Dina Zerem; Omar Zerem
Journal:  Clin Exp Hepatol       Date:  2022-03-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.